Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

740 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Davies M, et al. Among authors: shimomura i. Lancet. 2021 Mar 13;397(10278):971-984. doi: 10.1016/S0140-6736(21)00213-0. Epub 2021 Mar 2. Lancet. 2021. PMID: 33667417 Clinical Trial.
Three-month treatment with pioglitazone reduces circulating levels of S100A8/A9 (MRP8/14) complex, a biomarker of inflammation, without changes in body mass index, in type 2 diabetics with abdominal obesity.
Nakatsuji H, Kishida K, Funahashi T, Shimomura I; Senri Study II Group. Nakatsuji H, et al. Among authors: shimomura i. Diabetes Res Clin Pract. 2012 Mar;95(3):e58-60. doi: 10.1016/j.diabres.2011.11.018. Epub 2011 Dec 9. Diabetes Res Clin Pract. 2012. PMID: 22154375
Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.
Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I. Fujishima Y, et al. Among authors: shimomura i. Cardiovasc Diabetol. 2012 Sep 14;11:107. doi: 10.1186/1475-2840-11-107. Cardiovasc Diabetol. 2012. PMID: 22973968 Free PMC article.
Three-month treatment with pioglitazone reduces circulating C1q-binding adiponectin complex to total-adiponectin ratio, without changes in body mass index, in people with type 2 diabetes.
Nakatsuji H, Kishida K, Kobayashi H, Funahashi T, Shimomura I; Senri Study II Group. Nakatsuji H, et al. Among authors: shimomura i. Diabetes Res Clin Pract. 2013 Jan;99(1):e14-7. doi: 10.1016/j.diabres.2012.10.003. Epub 2012 Nov 9. Diabetes Res Clin Pract. 2013. PMID: 23142017 Clinical Trial.
740 results